Finally, while recognizing the importance of managing complications and risk factors associated with acromegaly, it may be that aggressive drug therapy in those with GH and/or IGF‐I values only marginally above target may not be warranted, particularly in those who develop disease later in life. The gene discussed is IGF1; the disease is acromegaly.